Alpelisib-Induced Diabetic Ketoacidosis: A Case Report and Review of Literature
CONCLUSION: Although PI3KCA inhibitors remain a promising drug in patients with metastatic breast cancer who have not responded to previous treatment, patients must be closely monitored for adverse effects such as hyperglycemia. Hyperglycemia could be a potentially limiting side effect of alpelisib. The optimal management of hyperglycemia induced by alpelisib warrants further research.PMID:34095470 | PMC:PMC8053625 | DOI:10.1016/j.aace.2020.11.028
Source: Clinical Genitourinary Cancer - Category: Cancer & Oncology Authors: Maritza Carrillo Renil M Rodriguez Christopher L Walsh Megan Mcgarvey Source Type: research
More News: Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Diabetes | Diets | Endocrinology | Insulin | Laboratory Medicine | Nutrition | Sugar